Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Absorption of WE 941 OD (Brotizolam) from Oral Mucosa
NCT02218671Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2000
- Primary completion
- Mar 2000
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of brotizolam in Insomnia (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Number of patients with adverse events up to 17 days. Started Mar 2000; status: completed.
02
Drugs
brotizolam
03
Conditions
Insomnia
Beyond the preview
Go deeper on NCT02218671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02218671.